Sunovion's Stedesa treads down monotherapy path
This article was originally published in Scrip
Sunovion's epilepsy treatment eslicarbazepine acetate has succeeded in two Phase III trials as a monotherapy in adult patients with partial-onset seizures with or without secondary generalization who were not well-controlled by current antiepileptic drugs, marking the first steps towards a possible expansion of the product's use.
You may also be interested in...
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.